Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis

References

• Shih DQ, Targan SR. Insights into IBD pathogenesis. Curr Gastroenterol Rep 2009;11:473–80.
   PubMedGoogle Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006;12:4807–12.
   PubMed Web of Science ®Google Scholar
• Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999;117:73–81.
   PubMed Web of Science ®Google Scholar
• Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27:987–91.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005;54:789–96.
   PubMed Web of Science ®Google Scholar
• Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, Buechler C, Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 2006;12:471–7.
   PubMed Web of Science ®Google Scholar
• Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007;19:1070–4.
   PubMed Web of Science ®Google Scholar
• Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9–17.
   PubMedGoogle Scholar
• Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011;106:748–61.
   PubMed Web of Science ®Google Scholar
• Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Anti-TNF antibodies target T-cell apoptosis in inflammatory bowel diseases via TNFR2 and intestinal CD14+ macrophages. Gastroenterology 2011;141:2026–38.
   PubMed Web of Science ®Google Scholar
• Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1476–84.
   PubMed Web of Science ®Google Scholar
• Gambero A, Maróstica M, Abdalla Saad MJ, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 2007;13:1357–64.
   PubMed Web of Science ®Google Scholar
• Thomaz MA, Acedo SC, de Oliveira CC, Pereira JA, Priolli DG, Saad MJ, Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. Pharmacol Res 2009;60:341–6.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Ossenkoppele GJ, Beelen RH, Broekhoven MG, Dräger AM, Langenhuijsen MM. Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. Exp Hematol 1993;21:1628–39.
   PubMed Web of Science ®Google Scholar
• Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res 2007;56:105–11.
   PubMedGoogle Scholar
• Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 1995;268:G622–30.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔC(T)) method. Methods 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685–98.
   PubMed Web of Science ®Google Scholar
• de Oliveira CC, Acedo SC, Pedrazzoli J Jr, Saad MJ, Gambero A. Depot-specific alterations to insulin signaling in mesenteric adipose tissue during intestinal inflammatory response. Int Immunopharmacol 2009;9:396–402.
   PubMedGoogle Scholar
• Acedo SC, Gotardo EM, Lacerda JM, de Oliveira CC, de Oliveira Carvalho P, Gambero A. Perinodal adipose tissue and mesenteric lymph node activation during reactivated TNBS-colitis in rats. Dig Dis Sci 2011;56:2545–52.
   PubMedGoogle Scholar
• Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A, Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005;11:6843–7.
   PubMed Web of Science ®Google Scholar
• Rosillo MA, Sanchez-Hidalgo M, Cárdeno A, de la Lastra CA. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol 2011;82:737–45.
   PubMed Web of Science ®Google Scholar
• Singh K, Chaturvedi R, Barry DP, Coburn LA, Asim M, Lewis ND, The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem 2011;286:3839–50.
   PubMedGoogle Scholar
• Schäffler A, Fürst A, Büchler C, Paul G, Rogler G, Schölmerich J, Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn's disease: regulation by steroid treatment. J Gastroenterol Hepatol 2006;21:1412–18.
   PubMed Web of Science ®Google Scholar
• Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012;42:95–109.
   PubMedGoogle Scholar
• Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472–6.
   PubMed Web of Science ®Google Scholar
• Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001;98:502–6.
   PubMed Web of Science ®Google Scholar
• Tiaka EK, Manolakis AC, Kapsoritakis AN, Potamianos SP. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev 2011;22:109–19.
   PubMedGoogle Scholar
• Cohen G, Ilic D, Raupachova J, Hörl WH. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol 2008;181:3761–8.
   PubMedGoogle Scholar
• Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, Palladino G, Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 2011;6:e22978.
   PubMed Web of Science ®Google Scholar
• Zulian A, Cancello R, Micheletto G, Gentilini D, Gilardini L, Danelli P, Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 2012;61:86–94.
   PubMed Web of Science ®Google Scholar
• De clercq L, Genart C, Boone C, Remacle C. Effects of acute or chronic administration of tumor necrosis factor on rat adipose tissue development. J Anim Sci 1996;74:2745–51.
   PubMedGoogle Scholar
• Isakson P, Hammarstedt A, Gustafson B, Smith U. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 2009;58:1550–7.
   PubMed Web of Science ®Google Scholar
• Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett 2010;584:3242–9.
   PubMed Web of Science ®Google Scholar